Canadian CANNAINVESTOR Magazine July / August 2017 - Page 216

References

Chen, J., & McCarron, R. (2013). Cannabinoid hyperemesis syndrome: A result of chronic, heavy Cannabis use. Current Psychiatry, 12(10), 48-54.

Rosenberg, E., Tsien, R., Whalley, B., & Devinsky, O. (2015). Cannabinoids and epilepsy. Neurotherapeutics, 12(4), 747-768.

De-Vries, N. Sloot, P. Achterberg, W. (2016). Pain and pain assessment in stroke patients with aphasia: A systematic review. Aphasia Outcomes: Beyond Measures of Language Performance, 31(6), 703-719.

Green, A. J., De-Vries, K. (2010). Cannabis use in palliative care – an examination of the evidence and the implications for nurses. Journal of Clinical Nursing, 19(17-18), 2454-2462.

Iversen, L. (2003). Cannabis and the brain. Brain, 126(6), 1252-1270.

Kalant, H., & Porath-Waller, A. (2012). Clearing the smoke on cannabis: Medical use of cannabis and cannabinoids. Ottawa, Ont: Canadian Centre on Substance Abuse, (5), 1-7.

Moreira, F., Grieb, M., & Lutz, B. (2009). Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Practice & Research Clinical Endocrinology & Metabolism, 23(1), 133-144.

Pertwee, R. (2007). Cannabinoids and multiple sclerosis. Molecular Neurobiology, 36(1), 45-59.

Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005). Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Journal of Neurology, 128(6), 1314-1322.

Zer-Aviv, T., Segev, A., & Akirav, I. (2016). Cannabinoids and post-traumatic stress disorder: Clinical and preclinical evidence for treatment and prevention. Behavioural Pharmacology, 27(7), 561-569.

216